New Alzheimer’s drug is first to show it slows disease. But It’s facing a rocky rollout

July 20, 2023

Eisai Co.’s breakthrough Alzheimer’s drug—the first to show it slows the brain-destroying disease—is facing a rocky rollout as doctors grapple with logistical issues, insurance uncertainties and complicated safety testing requirements.

ADHD: What parents need to know
Lots of children and adolescents have the condition known as ADHD, or attention-deficit/hyperactivity disorder.
Common plastics chemical could harm boys' development
Phthalates are commonly used in plastics, and researchers have now tied them to developmental issues in toddler boys who were exposed to the chemical in the womb.
Size of the mother and father found to impact the risk of having a big baby
If either you or your partner was a "big" baby, you have an increased likelihood of giving birth to a large baby yourself, a new study by researchers from the University of Bergen, Norway, shows. This could potentially improve prenatal care and interventions by identifying pregnancies at higher risk of obstetric complications during labor and delivery.
Evolution, culture and self-knowledge: Why is the study of human personality so important?
In the field of neuroscience, the D'Or Institute for Research and Education (IDOR) is known for research involving pathologies, from malformations to acquired maladies. The understanding of diseases, however, is not the only focus of the area, which is also committed to theoretical and evolutionary research on the human mind.
Study suggests single dose of psilocybin safe and effective as treatment for major depressive disorder
A collaboration between 34 researchers at 18 institutions has looked into the efficacy and safety of psilocybin in patients with major depressive disorder.

New Alzheimer’s drug is first to show it slows disease. But It’s facing a rocky rollout

Recent Posts

JUST IN